Inteliquet Spotlight: Joyce Emerson Cleary, MSN, MBA
FEATURED BLOG ARTICLE
Inteliquet Spotlight: Joyce Emerson Cleary, MSN, MBA
Joy is Inteliquet’s Vice President of Life Sciences and Strategic Account Management. Her career began as an oncology nurse and then she moved to implementing multiple phase I-III investigational clinical trials of various biologics and chemotherapeutics, including one of the first bone marrow transplant clinical research programs. From there, she went on to head up Medical Affairs and at global oncology biopharmaceutical companies.
We spoke to her about what she wants to achieve at Inteliquet, and why she believes that life sciences companies are critical agents for enabling powerful change around patient access to healthcare.
What drew you to clinical development and research?
It began with an interest in science and medicine. Early in my career I was a nurse at a pediatric academic, tertiary care hospital and worked with critically ill children with hematological malignancies and other genetic and rare diseases.
It is clear that clinical trials bring significant innovations in patient care. At the time when I was working in pediatric oncology, just 50% to 70% childhood acute lymphoblastic leukemia patients survived. The power of clinical trials and patient access to treatment through clinical trials was an important advancement to transforming survival rates to around 90%. Clinical trials have also brought significant improvements in diagnostics and symptom management across a number of oncology areas. Breast cancer is another notable area where combined modality therapies have been evaluated through clinical trials and where progress was driven by this work. In some instances, cancer is now considered a chronic disease, as opposed to being fatal. Working in pediatric hematology-oncology, particularly leukemia, drove me to secure a CRA position that led me to work on an early trial to address bone marrow transplant failure.
Cancer remains a major healthcare issue—most people are touched by it through someone close to them. It is the second leading cause of death. By 2025, there will be 30 million people living with cancer. It’s a huge burden to those living with cancer and to families—all of that drove me to find new ways to help make clinical research effective and help patients.
What made you join Inteliquet?
I saw that Inteliquet can make a difference in clinical development and patient enrollment. We provide an innovative technology-driven solution that brings together a unique combination of science, people and technology. Inteliquet supports life sciences, patients and providers to bring advances in therapies and improvements in curative cancer treatment.
I joined Inteliquet because I also saw how they had thought through the complexity of clinical issues in oncology trials and are using propriety technology to solve them. They understand the barriers in clinical trials—the day-to-day clinical operational flows and problems—and they know how to bring innovative technology and services together to match patients to clinical trials. Inteliquet understands the problems and is using technology to overcome them to enable more patients to access oncology trials.
What are the top challenges facing life sciences?
One challenge is matching and enrolling patients to novel therapies. It is a problem of opportunities—more potential therapies requiring more trials that have more complexity, and thus require more patients. But less patients are being enrolled in trials. And as you drill down to specific disease states, patient populations become more challenging to find, let alone match and identify.
Another challenge is a strategic planning issue, that is identifying patient populations and understanding their clinical journeys for development of agents and future therapies. Life Sciences require the right data to identify unmet needs and potential therapies while clarifying targeted potential patient pools. Linking real-time access to patients that may be candidates for a specific trial improves enrollment and is the key to improving clinical trial design and feasibility.
As a partner, Inteliquet can support biopharma’s clinical development work as well as help evaluate specific clinical trials feasibility. We can help with preplanning access to patient pools via our Clinical Consortium. And we partner with healthcare providers by screening for patients’ eligibility to clinical trials every day, so they have the opportunity to find right the best treatment and trials for their patients.
Is patient scarcity for trials really an issue?
No, the patients are there; the issue is accessing data to identify where the patients are. Eighty percent of cancer patients are treated at community cancer centers, though most sponsor-initiated trials are activated within large academic oncology centers.
Inteliquet’s Clinical Consortium includes oncology research programs across integrated delivery networks, community outpatient practices and academic networks. This improves patients access to clinical trials and sponsors access to patients. The Clinical Consortium comprises more than 1 million patients who are treated at community oncology practices and hospitals, integrated delivery networks and academic medical centers.
We offer de-identified real-world primary data with the granularity to provide significant data, such as biomarker status, specific agents, patient journey, and treatment results. These types of data are also valuable in providing real-world evidence for FDA submissions, which can expedite clinical development and trials negotiations.
What is it that you want Life Science leaders to know?
Partnering with Inteliquet brings clarity to the goal of enrolling patients in clinical trials more quickly. We have the right technology that makes clinical trials patient-centric. We can prescreen patients through our proprietary platform, Artificial Intelligence (AI) and site electronic health records, which can improve patient care management, productivity, and patient access to clinical trial enrollment.
As a partner, we also bring significant value with our enhanced data and insights, technology and expert services. Utilizing our real-world, real-time, primary data along with our enhanced data and insights, we provide a powerful solution for Life Sciences in addressing questions of patient population landscapes, real world treatment paradigms—and a solution in creating Real World Evidence through Real World Data.